Should we, and how to, optimize cefiderocol administration during severe nosocomial pneumonia due to carbapenem-resistant Acinetobacter baumanii? A viewpoint.

Julien MassolAurélien DinhKaty JeannotClara DuranFrédérique BouchandAnaïs PotronLaurent DortetFrançois Jehl

Published in: Journal of global antimicrobial resistance (2024)

Further research is needed to determine the optimal cefiderocol dosage and administration (mono vs. dual therapy, continuous vs. intermittent infusion), in severe Acinetobacter baumannii nosocomial pneumonia.

Keyphrases

acinetobacter baumannii
multidrug resistant
gram negative
drug resistant
pseudomonas aeruginosa
early onset
klebsiella pneumoniae
low dose
drug induced
high intensity
respiratory failure
escherichia coli
mesenchymal stem cells
cell therapy